TAKE Solutions Limited (TAKE.NS)
INR 8.95
(1.7%)
INR 8.95
(1.7%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 969.78 Million INR | -16.24% |
| 2022 | 1.15 Billion INR | -88.89% |
| 2021 | 10.42 Billion INR | 44.73% |
| 2020 | 7.2 Billion INR | -19.78% |
| 2019 | 8.97 Billion INR | 11.33% |
| 2018 | 8.06 Billion INR | 59.11% |
| 2017 | 5.06 Billion INR | 18.87% |
| 2016 | 4.26 Billion INR | -21.46% |
| 2015 | 5.42 Billion INR | 58.8% |
| 2014 | 3.41 Billion INR | -3.12% |
| 2013 | 3.52 Billion INR | -4.79% |
| 2012 | 3.7 Billion INR | 2.66% |
| 2011 | 3.61 Billion INR | 10.71% |
| 2010 | 3.26 Billion INR | 155.21% |
| 2009 | 1.27 Billion INR | -1.12% |
| 2008 | 1.29 Billion INR | 30.01% |
| 2007 | 994.13 Million INR | -41.49% |
| 2006 | 1.69 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q2 | 1.11 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 969.78 Million INR | -16.24% |
| 2023 Q4 | 969.78 Million INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2022 Q2 | 1.58 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 1.15 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 1.15 Billion INR | -88.89% |
| 2021 Q2 | 7.4 Billion INR | 0.0% |
| 2021 Q4 | 10.42 Billion INR | 0.0% |
| 2021 FY | 10.42 Billion INR | 44.73% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q4 | 7.2 Billion INR | 0.0% |
| 2020 Q2 | 8.38 Billion INR | 0.0% |
| 2020 FY | 7.2 Billion INR | -19.78% |
| 2020 Q3 | - INR | -100.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 9.28 Billion INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q4 | 8.97 Billion INR | 0.0% |
| 2019 FY | 8.97 Billion INR | 11.33% |
| 2018 Q2 | 5.86 Billion INR | 0.0% |
| 2018 FY | 8.06 Billion INR | 59.11% |
| 2018 Q4 | 8.06 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q1 | - INR | -100.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 5.03 Billion INR | 0.0% |
| 2017 FY | 5.06 Billion INR | 18.87% |
| 2017 Q4 | 5.06 Billion INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q4 | 4.26 Billion INR | 0.0% |
| 2016 Q2 | 4.16 Billion INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 FY | 4.26 Billion INR | -21.46% |
| 2015 FY | 5.42 Billion INR | 58.8% |
| 2015 Q4 | 5.42 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q2 | 3.48 Billion INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2014 Q2 | 3.49 Billion INR | 0.0% |
| 2014 FY | 3.41 Billion INR | -3.12% |
| 2014 Q4 | 3.41 Billion INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q1 | - INR | -100.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 FY | 3.52 Billion INR | -4.79% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q2 | 3.55 Billion INR | 0.0% |
| 2013 Q4 | 3.52 Billion INR | 0.0% |
| 2012 FY | 3.7 Billion INR | 2.66% |
| 2012 Q4 | 3.7 Billion INR | 0.0% |
| 2012 Q3 | - INR | -100.0% |
| 2012 Q2 | 3.96 Billion INR | 0.0% |
| 2011 FY | 3.61 Billion INR | 10.71% |
| 2011 Q4 | 3.61 Billion INR | 0.0% |
| 2010 FY | 3.26 Billion INR | 155.21% |
| 2009 FY | 1.27 Billion INR | -1.12% |
| 2008 FY | 1.29 Billion INR | 30.01% |
| 2007 FY | 994.13 Million INR | -41.49% |
| 2006 FY | 1.69 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Biocon Limited | 307.95 Billion INR | 99.685% |
| Blue Jet Healthcare Limited | 2.13 Billion INR | 54.603% |
| Concord Biotech Limited | 1.74 Billion INR | 44.286% |
| Dishman Carbogen Amcis Limited | 39.53 Billion INR | 97.547% |
| Jubilant Ingrevia Limited | 19.94 Billion INR | 95.138% |
| Lyka Labs Limited | 884.58 Million INR | -9.631% |
| Panacea Biotec Limited | 4.02 Billion INR | 75.877% |
| Piramal Pharma Limited | 74 Billion INR | 98.69% |
| SMS Lifesciences India Limited | 1.96 Billion INR | 50.743% |
| Supriya Lifescience Limited | 1.05 Billion INR | 8.399% |
| Syngene International Limited | 18.93 Billion INR | 94.879% |
| Zota Health Care Limited | 1.38 Billion INR | 29.905% |